<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01076322</url>
  </required_header>
  <id_info>
    <org_study_id>002-TWB-0801</org_study_id>
    <nct_id>NCT01076322</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and Safety of Meptin® Swinghaler® and Ventolin® MDI in Stable Asthma Patients</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taiwan Otsuka Pharm. Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taiwan Otsuka Pharm. Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, randomized, cross-over, active-controlled study to evaluate the&#xD;
      efficacy and safety effects using Meptin® Swinghaler and Ventolin® MDI in stable asthma&#xD;
      patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change in Forced Expiratory Volume in 1 second (FEV1) value.</measure>
    <time_frame>2 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The change in sGaw</measure>
    <time_frame>2 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The changes in IOS parameters (R, X and RF)</measure>
    <time_frame>2 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in Peak Expiratory Flow Rate (PEFR)</measure>
    <time_frame>2 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in Forced Vital Capacity (FVC)</measure>
    <time_frame>2 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in Oxygen Saturation (SpO2)</measure>
    <time_frame>2 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in Borg scale</measure>
    <time_frame>2 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device acceptance</measure>
    <time_frame>2 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">17</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Treatment-A sequence</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Meptin® Swinghaler / Ventolin® MDI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment-B sequence</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ventolin® MDI / Meptin® Swinghaler</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meptin® Swinghaler</intervention_name>
    <description>Meptin® Swinghaler®&#xD;
Ingredient: Procaterol HCL&#xD;
Dosage form: 10g/puff&#xD;
Dose(s): 10g&#xD;
Dosing schedule: 20g (total 20g)</description>
    <arm_group_label>Treatment-A sequence</arm_group_label>
    <arm_group_label>Treatment-B sequence</arm_group_label>
    <other_name>Meptin® Swinghaler®</other_name>
    <other_name>Procaterol HCL</other_name>
    <other_name>Ventolin® MDI</other_name>
    <other_name>Salbutamol sulfate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ventolin® MDI</intervention_name>
    <description>Ventolin® MDI&#xD;
Ingredient: Salbutamol sulfate&#xD;
Dosage form: 100g/puff&#xD;
Dose(s): 100g&#xD;
Dosing schedule: 200g (total 200g)</description>
    <arm_group_label>Treatment-A sequence</arm_group_label>
    <arm_group_label>Treatment-B sequence</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or females outpatients aged ≥ 16 years old with stable mild to moderate&#xD;
             persistent asthma; Stability was assessed the patient remained in the same severity&#xD;
             class (mild, moderate) and had no acute exacerbations by investigator judgment during&#xD;
             the past 14 days;&#xD;
&#xD;
          2. Pulmonary function test:&#xD;
&#xD;
               -  Improvement ≥12% reversibility in FEV1 or FVC following administration of an&#xD;
                  inhaled β2-agonist before the study or ;&#xD;
&#xD;
               -  Positive result of Broncho-provocation test (PC20 ≤ 32 mg/ml) before the study.&#xD;
&#xD;
          3. Baseline forced expiratory volume in one second 60% ≤(FEV1)≤ 90% of predicted value on&#xD;
             entry of the study;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Hypersensitivity to β2-agonist or lactose;&#xD;
&#xD;
          2. Hospitalization due to asthma during the previous 3months;&#xD;
&#xD;
          3. Respiratory tract infection requiring treatment with antibiotics in the previous 4&#xD;
             weeks;&#xD;
&#xD;
          4. Oral or systemic corticosteroids in the previous 4weeks;&#xD;
&#xD;
          5. Inadequately controlled hyperthyroidism;&#xD;
&#xD;
          6. Severe hepatic or renal or cardiovascular disease as judged by the investigator;&#xD;
&#xD;
          7. Patients receive an investigational drug within 30 days prior to admission to the&#xD;
             study;&#xD;
&#xD;
          8. Patients with significant alcohol, drug or medication abuse as judged by the&#xD;
             investigator;&#xD;
&#xD;
          9. Females who are pregnant or breast-feeding; (exception: Females of child-bearing age&#xD;
             might be included, if in the opinion of the investigator, they are using adequate&#xD;
             contraceptive precautions).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ping-Hung Kuo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>February 2010</verification_date>
  <study_first_submitted>February 24, 2010</study_first_submitted>
  <study_first_submitted_qc>February 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2010</study_first_posted>
  <last_update_submitted>August 10, 2010</last_update_submitted>
  <last_update_submitted_qc>August 10, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 12, 2010</last_update_posted>
  <responsible_party>
    <name_title>Edward C.Y. Peng</name_title>
    <organization>Taiwan Otsuka Pharmaceutical Co., Ltd</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Albuterol</mesh_term>
    <mesh_term>Procaterol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

